Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 11/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2198979 | 0.87 | IGF1R (0.38) | MAPK9ADRB2ADRB1CYP2D6NFKB1 | |
| SCHEMBL2195962 | 0.87 | FLT3 (0.44) | FLT3MAPK9MAPK8 | |
| SCHEMBL2198230 | 0.86 | ADRB2 (0.35) | FLT3ADRB2ADRB1CYP2D6NFKB1 | |
| SCHEMBL2195698 | 0.85 | IGF1R (0.36) | ADRB2ADRB1CYP2D6NFKB1HIF1A | |
| SCHEMBL4258682 | 0.83 | IGF1R (0.35) | ADRB2ADRB1CYP2D6NFKB1HIF1A | |
| SCHEMBL2200557 | 0.83 | IGF1R (0.35) | ADRB2ADRB1CYP2D6NFKB1HIF1A | |
| SCHEMBL2197154 | 0.83 | IGF1R (0.35) | ADRB2ADRB1CYP2D6NFKB1HIF1A | |
| SCHEMBL2198357 | 0.83 | IGF1R (0.35) | ADRB2ADRB1CYP2D6NFKB1HIF1A | |
| SCHEMBL2195588 | 0.78 | IGF1R (0.33) | FLT3ADRB1 | |
| SCHEMBL2197982 | 0.78 | CDK2 (0.37) | MAPK9MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977336-B2 | Aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO. LTD (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2116543-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVE AS PLK1 INHIBITOR | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | PLK1, AURKA, CDK1 | FLT3 197/4885EGFR 1076/4885MAPK9 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.